MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition
|
results as of and for the quarter ended March 31, 2017. The full
text of the press release issued in connection with the
announcement is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
99.1) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
(d) Exhibits.
|
|
99.1
|
Press Release issued by the Company on May 3, 2017
|
About MACROGENICS, INC. (NASDAQ:MGNX)
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers. MACROGENICS, INC. (NASDAQ:MGNX) Recent Trading Information
MACROGENICS, INC. (NASDAQ:MGNX) closed its last trading session down -0.20 at 21.35 with 226,324 shares trading hands.